XORTX Therapeutics (XRTX) Restructuring Costs (2022 - 2026)

XORTX Therapeutics' Restructuring Costs history runs 5 years deep, the most recent figure standing at $47474.0 for Q1 2026.

• Quarterly Restructuring Costs changed N/A year-over-year to $47474.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19411.4 (changed N/A YoY) and the FY2025 annual result came in at $86126.3, down 16.61% from the prior year.
• Restructuring Costs was $47474.0 for Q1 2026 at XORTX Therapeutics, up from $22592.0 in the prior quarter.
• Across five years, Restructuring Costs topped out at $47474.0 in Q1 2026 and bottomed at -$81477.6 in Q4 2023.
• A 5-year average of $19713.9 and a median of $29728.9 in 2022 frame the typical range for Restructuring Costs.
• Peak annual rise in Restructuring Costs reached 77.57% in 2023, while the deepest fall reached 453.57% in 2023.
• XORTX Therapeutics' Restructuring Costs stood at $23044.1 in 2022, then sank by 453.57% to -$81477.6 in 2023, then surged by 137.83% to $30823.0 in 2024, then fell by 26.7% to $22592.0 in 2025, then soared by 110.14% to $47474.0 in 2026.
• Business Quant data shows XRTX's Restructuring Costs at $47474.0 in Q1 2026, $22592.0 in Q3 2025, and $30823.0 in Q3 2024.